Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology
Disease Category: Epilepsy
Trial Information
Phase 3 Study to Evaluate Efficacy and Safety of Oxcarbazepine Extended-Release in Subjects With Refractory Partial Seizures Due to Epilepsy When Used With up to 2 Other Antiepileptic Drugs.
This is a multicenter, double-blind, randomized, placebo-controlled three-arm parallel group study (1200 mg/day and 2400 mg/day) with the choice for eligible subjects to enroll into an open-label extension study. The duration of the study is expected to be approximately 23 to 35 weeks.
Participants can be male or female between the ages of 18 to 65 years. Participants must have a diagnosis of partial onset seizures with or without secondarily generalized seizures as confirmed by the 1981 and 1989 International League Against Epilepsy [ILAE] Classifications. Participants must be currently taking at least one and up to two AEDs with AED therapy remaining at a stable dose for at least four weeks prior to Baseline.
Participants should be in good health with no psychiatric conditions.
Lilly Rousseva
Pacific Institute for Medical Research, Inc
10921 Wilshire Blvd., Ste 702
Los Angeles, CA 90024
Phone: 310-208-7144
Fax: 310-209-0444
EMail: lillyrs@hotmail.com
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
